DUBLIN–(BUSINESS WIRE)–Feb 4, 2021–
The "Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report by Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com’s offering.
The global castrate-resistant prostate cancer market size is expected to reach USD 16.2 billion by 2027. The market is expected to expand at a CAGR of 8.4% from 2020 to 2027. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.
In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.
The hormonal therapy segment dominated the market and held the largest revenue share of 83.1% in 2019. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.
North America’s dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Astellas Pharma, Inc.
- Bayer AG
Castrate-resistant Prostate Cancer Market Report Highlights
- Prostate cancer is the highest prevalent cancer in men. 1 in 9 men are diagnosed with prostate cancer.
- Within 3 years of diagnosis, 10-50% of overall prostate cancer cases develop into metastatic castrate-resistant prostate cancer.
- The recommendation of products from healthcare authorities is expected to increase the sales of the drug, thereby fueling market growth. For instance, Provenge is recommended by the Society for Immunotherapy of Cancer, the National Comprehensive Cancer Network, and the American Urological Association.
- Australia and New Zealand have the highest prevalence rate of the disease, followed by North America and Europe.
- In Asia Pacific, the market is likely to witness the fastest CAGR of 11.5% from 2020 to 2027.
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Castrate-Resistant Prostate Cancer Market Variables, Trends & Scope
3.1. Castrate-Resistant Prostate Cancer Market Lineage outlook
3.1.1. Parent market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. User Perspective Analysis
3.4. Regulatory Framework
3.5. Market Dynamics
3.5.1. Market driver analysis
22.214.171.124. Rising prevalence of castrate-resistant prostate cancer
126.96.36.199. Increasing technological advancements
188.8.131.52. Rising adoption of treatment
3.5.2. Market restraint analysis
184.108.40.206. Lack of standard therapy
3.6. Castrate-Resistant Prostate Cancer Market Analysis Tools
3.6.1. Industry Analysis – Porter’s
220.127.116.11. Supplier Power
18.104.22.168. Buyer Power
22.214.171.124. Substitution Threat
126.96.36.199. Threat from New Entrant
188.8.131.52. Competitive Rivalry
3.6.2. PESTEL Analysis
184.108.40.206. Political Landscape
220.127.116.11. Environmental Landscape
18.104.22.168. Social Landscape
22.214.171.124. Technology Landscape
126.96.36.199. Legal Landscape
Chapter 4. Castrate-Resistant Prostate Cancer Market: Therapy Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Therapy Market Share Analysis, 2019 & 2027
4.3. Therapy Dashboard
4.4. Castrate-Resistant Prostate Cancer Market, By Therapy, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
Chapter 5. Castrate-resistant Prostate Cancer Market: Segment Analysis, By Region, 2016 – 2027 (USD Million)
5.1 Castrate-resistant Prostate Cancer Market, Market Share by Region, 2019 & 2027
5.1.1 North America
5.1.3 Asia Pacific
5.1.4 Latin America
5.1.5 Middle East and Africa
Chapter 6. Company Profiles
6.1. Recent developments & impact analysis, by key market participants
6.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
6.3. Public Companies
6.4. Private Companies
6.5. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/k48r4p
View source version on businesswire.com:https://www.businesswire.com/news/home/20210204005753/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: RADIOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/04/2021 10:04 AM/DISC: 02/04/2021 10:04 AM